

Christina Lake Cannabis Corp.
Management Discussion & Analysis
(Expressed in Canadian Dollars)

For the fiscal year ended November 30, 2021 and 2020

Prepared April 13, 2022

This Management Discussion & Analysis ("MD&A") is provided to enable the reader to assess material changes in the financial condition and results of operations of Christina Lake Cannabis Corp. (the "Company") for the year ended November 30, 2021. This MD&A should be read in conjunction with the audited consolidated financial statements for the year ended November 30, 2021 ("Financial Statements") and the audited consolidated financial statements of the company for the year ended November 30, 2020, prepared in accordance with international financial reporting standards ("IFRS") as issued by the international accounting standards board ("IASB"). This MD&A complements and supplements but does not form part of the company's consolidated financial statements.

Our financial statements and the management's discussion and analysis are intended to provide a reasonable base for the investor to evaluate our financial situation.

All dollar amounts contained in this MD&A are expressed in Canadian dollars, unless otherwise specified.

Where we say "we", "us", "our", the "Company" we mean Christina Lake Cannabis Corp., as it may apply.

OVERVIEW

Christina Lake Cannabis Corp. (the "Company") was incorporated on October 26, 2014, under the laws of the province of British Columbia, Canada. On December 21, 2018, the Company changed its name from Cervantes Capital Corp. to Christina Lake Cannabis Corp. The Company is a licensed producer of cannabis in British Columbia under the Cannabis Act with a standard cultivation, processing and sales license and a research and development license. On October 1, the Company began trading on the Canadian Securities Exchange under the ticker symbol "CLC." The Company has received approval from OTC Markets Group Inc. ("OTCM") for its shares to trade on the OTCQB® exchange ("OTCQB") beginning at market open on Thursday February 18, 2021

The Company is a reporting Company in British Columbia and Alberta effective as of December 3, 2014. The Company's registered and records office is Suite 810 – 789 West Pender Street, Vancouver, BC, V6C 1H2, Canada.

Management is responsible for the preparation and integrity of the financial statements, including the maintenance of appropriate information systems, procedures and internal controls. Management is also responsible for ensuring that information disclosed externally, including financial statements and Management Discussion and Analysis ("MD&A"), is complete and reliable.

This discussion contains forward-looking statements that involve risks and uncertainties. Such information, although considered to be reasonable by the Company's management at the time of preparation, may prove to be inaccurate and actual results may differ materially from those anticipated in the statements made. Additional information on the Company is available for viewing on SEDAR at www.sedar.com.

DESCRIPTION OF BUSINESS

The Company is a licensed cannabis producer and obtained a Standard Cannabis Cultivation License on March 27, 2020, which is further augmented by a Processing Amendment obtained September 11, 2020. The Company also has its Research and Development License (an "RDL") from Health Canada. The Company is currently engaged in the processing of its stock of dried Cannabis biomass into various extracts including Distilled & Winterized Oils, Kief, and additional extracted products for sale to other Licensed Producers.

HIGHLIGHTS

The Company, a premier producer of consistent high-quality, low cost, sun-grown cannabis flower, oil cannabinoids, as well as hemp-based extracts and derivatives, serving domestic and international cannabinoid markets.

- On March 31, 2022, the Company announced that because of delays of its audit of the Company's annual financial statements and management's discussion and analysis for the fiscal year ending November 30, 2021, the Company applied for and was granted a management cease trade order by the British Columbia Securities Commission. The delay is to the complexity of the valuation process of biological assets and inventory because of significant operational growth in the fiscal year.
- On March 29, 2022, the Company announced that further to the press release dated March 22, 2022, the Company has closed the redemption of the Class B Preferred Shares in accordance with the redemption notice provided on March 21, 2022.

In connection with the redemption, the preferred holders were issued in aggregate:

- (i) a secured promissory note in the amount of \$2,000,000 which will bear interest at a rate of 8% per annum and mature on October 31, 2024; and
- (ii) 13,000,000 common shares in the capital of the Corporation at a deemed price of \$0.20 per common share.

Following the redemption and payment of the redemption price to the preferred holders, all of the outstanding preferred shares were cancelled. 2260994 Alberta Ltd., the general partner of Excalibur Technologies L.P., is a company controlled by Mervin Boychuk, ultimately received an aggregate of 920,485 common shares in connection with the redemption. Accordingly, the redemption constituted to that extent a related party transaction. In conjunction with the close, the Company elected to repay \$250,000 plus interest of \$48,383.56 to reduce the total amount owing under the Promissory note issued. The remaining balance is \$1,750,000 which will bear interest at a rate of 8% per annum noted above.

- On March 22, 2022 the Company announced that the board of directors of the Corporation has provided notice to the holders of Preferred Shares, for a compulsory redemption of their Preferred Shares.
- On March 15, 2022, the Company announced it had appointed Jay McMillan to its Board of Directors. Mr. McMillan's most recent role was as Chief Development Officer with Hexo Corp. a leading Canadian Licensed Producer of Cannabis. Mr. McMillan identified strategic business development opportunities by way of M&A, joint ventures, and key partnerships.

The Company also announced that it had issued 200,000 Restricted Share Units ("RSUs") and 675,000 Stock Options to directors and employees of the Company in accordance with the Company's Stock Option & RSU plan. 300,000 Stock Options were granted with an exercise price of \$0.20 per common share for a 5-year term and 375,000 Stock Options with an exercise price of \$0.20 per common share for a 5-year term.

- On February 17, 2022, the Company announced that the special meeting date was postponed until March 11, 2022. The record date for the meeting was unchanged.
- On January 17, 2022, the Company announced a special meeting of Class B Preferred Shareholders to be held on February 21, 2022 and that the board of directors has fixed the record date on January 20, 2022.

HIGHLIGHTS (CONTINUED)

- On December 17, 2021, the Company announced an extension of the expiry date of a total of 6,981,299 purchase warrants with an exercise price of \$0.40 per common share extending the maturity date from December 31, 2021 to December 31, 2022.
- On October 26, 2021, the Company successfully completed harvesting its second crop which has already proven to be a higher yield than the inaugural crop with better quality biomass derived through enhanced harvesting techniques.
- On September 30, 2021, the Company granted 1,000,000 RSUs to the "Director of Sales" of the Company. 250,000 of the RSUs vested upon issuance, with the balance to vest in three increments of 250,000 over 18 months. The RSUs were priced at \$0.37 based on the closing price of the common shares on the Canadian Securities Exchange on September 29, 2021.
- On July 14, 2021 the Company provided an operational update pertaining to the 2021 growing season in which the Company is cultivated a large quantity of clones and seedlings outdoors in natural sunlight. In addition to the seven proprietary cannabis strains which comprise the majority of CLC's plants being grown in 2021, more than 90 experimental strains were also under observation in the field.
- On June 29, 2021 the Company announced that it succeeded in its efforts to consistently produce cannabis distillate oils with a tetrahydrocannabinol ("THC") concentration of 90% or higher, an industry benchmark that is considered to be a highly prestigious in the vaping industry.
- On June 15, 2021 the Company announced that it was in the process of transferring over 45,000 plants from its onsite greenhouse facility to the field area for transplantation.
- On June 8, 2021 the Company announced it had closed a non-brokered private placement of 6,283,813 units at a price of \$0.42 per unit for gross proceeds of \$2,639,201.26. Each unit consisted of one common share and one-half of one transferable share purchase warrant. Each warrant entitles the holder to purchase one additional share at a price of \$0.65 per share for a period of 30 months from the date of issuance. In the event that the shares have a closing price of \$1.10 or greater per share for a period of 10 consecutive trading days at any time from the closing of the private placement, the Company may accelerate the expiry date of the Warrants by giving notice to the holders by disseminating a news release. Finder's fees of \$34,020 cash, 81,000 warrants and 230,546 units have been paid in connection with the private placement.
- On June 7, 2021 the Company also announced the issuance of 445,000 shares to three individuals including the Company's President and a Director in satisfaction of certain consulting agreements.
- On June 7, 2021 the Company announced that Ray Baterina has been appointed as the Company's Corporate Secretary. Mr. Baterina has over 20 years experience in administrative and corporate services.
- On May 19, 2021 the Company provided several updates including as part of the Company's R&D processes, "clones" of several new cannabis strains developed using proprietary cannabis genetics have completed an observation period which growth has shown to be satisfactory for full-scale cultivation. Preparation of the field to begin the 2021 growing season also commenced. The company was preparing to add approximately 15% more plants in the same space.
- On May 4, 2021 the Company announced that it received its first purchase order for a commercial quantity of distillate oil valued at CAD \$129,000 from a Canadian Licensed Producer.
- On March 31, 2021 the Company announced that it nearly tripled its Cannabis Extraction Capacity with the industry's first installation of Vitalis' Cosolvent Injection System add-on.

HIGHLIGHTS (CONTINUED)

- On March 26, 2021 the Company announced that Salvatore Milia has been appointed to the Company's Board of Directors. Mr. Milia had received clearance from Health Canada to enter this capacity with the official appointment pending, which was finalized during the same week. Mr. Milia is currently leading the Company's research and development committee.
- On March 18, 2021, the Company announced the appointment of Rob Jones, an accomplished global trader of agriculture commodities, as the President of CLC to lead its commercialization efforts beginning in 2021 as the Company seeks to introduce its dried cannabis biomass and extracts to the market following an exceptionally successful inaugural harvest.
- On February 24, 2021, the Company announced it had entered in a memorandum of understanding ("MOU") with TAAT Lifestyle & Wellness Ltd. in which the Company is to develop and distribute the TAAT nicotine-free and tobacco-free alternative to tobacco cigarettes for the Canadian market.
- On February 18, 2021, the Company announced it received approval from OTC Markets Group Inc. ("OTCM") for its shares to trade on the OTCQB exchange ("OTCQB").
- The Company also has on hand a full state of ancillary equipment enabling its extraction team to take production through to the distillate and isolate phases.
- The Company's state-of-the-art extraction machinery, provides for high throughput capacity and substantial capacity to carry out the Company's organic and aggressive expansion strategy.
- The majority of the Company's harvest will be refined into full spectrum oil, distillates, and isolates to be sold in the wholesale markets,
- As the region's largest employer, the Company's team has expanded to over 30 full-time staff members and seasonal workers.
- On its 32-Acre site, the Company has commenced harvest of over 22,500 cannabis plants consisting of eight cannabis strains. Many plants are showing high yields, with some presently over eight feet tall.
- The total harvest for 2020 was completed in October yielding 32,500 kg of dried Cannabis, with growth in production expected for 2021 and beyond.
- On October 1, 2020, the Company commenced trading on the CSE under the ticker symbol "CLC".

BUSINESS DEVELOPMENT

- On January 11, 2022, the Company announced the yield numbers from the second growing season in 2021 which resulted in an overall yield of approximately 38,000 kg of dried biomass roughly 15% higher than the inaugural harvest in 2020.
- On October 26, 2021, the Company grew its proprietary outdoor strains on an extended footprint and saw enhanced THC yields in its proprietary strains as well as further improved yields by virtue of introducing additional automation while enhancing pre-processing techniques.
- The announcement on March 31, 2021 completed an eight-week, controlled testing period for a Cosolvent Injection System ("CIS") add-on developed by Vitalis Extraction Technology, Inc. ("Vitalis") enhancing the performance of its CO2 extraction machinery. This installation of the Vitalis CIS is the first of its kind in the cannabis industry. This technology nearly triples the Company's Cannabis Extraction Capacity.

BUSINESS DEVELOPMENT (Continued)

- During January 2021, the Company appointed Salvatore Milia to the Board of Directors. Mr. Milia has a background in building large-scale Information Technology systems, having designed, implemented and managed technical systems and networks for one of Canada's first non-bank credit card gateways and the Conservative Party of Canada.
- During December 2020, the Company appointed Gil Playford to the Board of Directors. As the Chairman of the Audit and Finance Committee Mr. Playford, an internationally accomplished senior corporate executive, previously served as the former Chairman and CEO of Union Carbide Corp, GrafTech, and LionOre.
- On October 26, 2020, the Company announced that it had exceeded its first annual Cannabis production target by 10,000 Kg. This represented an improvement 44% over its 2020 target, for a total harvested amount of 32,500 Kg of dried Cannabis.
- On October 15, 2020, the Company announced that it has completed the commissioning of its Vitalis Extraction Technology R200H-GMP-SS extraction system, which will be used to produce premium quality extracts in the form of full-spectrum cannabis oil, distillates and terpenes.
- During October 2020, the Company appointed Ryan Smith as the Chief Financial Officer. Mr. Smith a finance professional with a diversified business history primarily in the Banking and Telecommunication sectors both in Canada and the United States.
- During October 2020, the Company appointed Mervin Boychuk to the board of directors. Mr. Boychuk, a serial entrepreneur, has founded, built and sold four operational businesses in his 35-year career.
- During October 2020 the Company hired Rob Jones as Executive Vice President of Business Development and Sales along with Milan Stefancik as Director of Sales and Marketing. Mr. Jones has extensive experience in management and operations in the rendering business. Mr. Stefancik has served in a range of sales positions including most recently with Aurora Cannabis.
- During September 2020, the Company announced third-party service providers for investor relations, public relations as well as various production and management services for digital and social media.

BUSINESS DEVELOPMENT – FINANCING

During the year ended November 30, 2021, the Company successfully raised \$5,056,577 (2020 - \$9,203,219) in cash through financing activities, to fund its operations, purchase critical equipment, and expand the company's cultivation & processing facilities. The Company's working capital position was \$2,033,054 (November 30, 2020 - \$6,453,751).

PREFERRED SHARE AMENDMENT

Subsequent to the year ended November 30, 2021, the Corporation announced certain amendments to the terms of its class B preferred shares, the board of directors of the Corporation has closed the redemption of the class B preferred shares, for a compulsory redemption of their preferred shares, in accordance with the revised terms of the preferred shares.

PREFERRED SHARE AMENDMENT (CONTINUED)

In connection with the redemption, the preferred holders were issued in aggregate:

- (i) a secured promissory note in the amount of \$2,000,000 which will bear interest at a rate of 8% per annum and mature on October 31, 2024; and
- (ii) 13,000,000 common shares in the capital of the Corporation at a deemed price of \$0.20 per common share.

Following the redemption and payment of the redemption price to the preferred holders, all of the outstanding preferred shares will be cancelled. 2260994 Alberta Ltd., the general partner of Excalibur Technologies L.P., is a company controlled by Mervin Boychuk, ultimately received an aggregate of 920,485 common shares in connection with the redemption. Accordingly, the redemption constituted to that extent a related party transaction.

CONVERTIBLE DEBENTURE AMENDMENT

Additionally, the Company announced subsequent to the year ended November 30, 2021 that it has amended the terms of the following unsecured convertible debentures:

- 358 convertible debentures issued on March 13, 2020 in the principal amount of \$1,790,000;
- 158 convertible debentures issued on March 23, 2020 in the principal amount of \$790,000;
- 20 convertible debentures issued on April 7, 2020 in the principal amount of \$100,000;
- 5 convertible debentures issued on May 14, 2020 in the principal amount of \$25,000;
- 50 convertible debentures issued on May 25, 2020 in the principal amount of \$250,000; and
- 38.5 convertible debentures issued on August 20, 2020 in the principal amount of \$192,500.

The convertible debentures mature twenty-four months from the date of issuance and bear interest at a rate of 12% per annum. Under the amended terms, the Convertible Debentures will now mature forty-two months from the date of issuance and the debenture holder will have the option to convert unpaid and accrued interest into conversion shares at a price of \$0.20, and, regardless of the date of conversion, such holder will receive interest payable in conversion shares that is an amount equal to the unpaid interest for the period from the issue date, or date of last interest payment, if later, up to and including the maturity date, on a non pro rata basis. All other terms of the convertible debentures remain unchanged. The total principal amount outstanding under the convertible debentures amendment is \$3,147,500.

Convertible Debentures that have not been extended will remain subject to the original terms from issuance. The amendment to the Convertible Debenture will allow the Company to preserve its capital for operational activities.

BUSINESS OBJECTIVES AND OUTLOOK

The Company achieved several key milestones during the year ended November 30, 2021, including establishing a sales department and building upon its customer base for its cannabis products. The Company was able to optimize processing techniques which lead to consistent production of high potency distilled oils and other extracts, while adding additional processing capacity. Fiscal 2021 was the first year the Company established a commercial inventory for the sale of premium extracts and cannabis products. It was also the first year engaging in sales of those products, and year to date the Company has demonstrated significant quarter over quarter revenue growth. The Company intends to finish processing its remaining biomass from the inaugural 2020 crop, and will look to accelerate processing of its second ("2021") crop. As markets open up and restrictions ease, the sales team is poised to expand the Company's reach across all provinces in Canada, and is also looking to penetrate markets abroad.

SELECTED ANNUAL INFORMATION

The following table summarizes selected financial data for the Company for each of the three most recently completed financial years. The information set forth below should be read in conjunction with the Financial Statements. Financial Statements for all years presented are prepared in accordance with IFRS.

Fiscal years ended	November 30, 2021 \$	November 30, 2020 \$	November 30, 2019 \$
Total revenue	3,633,450	-	-
Total current assets	9,424,318	8,268,936	1,022,456
Total assets	18,968,891	17,803,786	6,202,790
Total non-current liabilities	1,838,438	6,533,348	-
Total liabilities	9,229,702	8,348,533	421,467
Net loss for the year	7,142,945	2,852,639	2,162,312
Basic and diluted loss per share	(0.07)	(0.04)	(0.04)

- The net loss for the year ended November 30, 2021 increased to \$7,142,945 (2020 \$2,852,639). During the year ended November 30, 2021, the Company incurred an inventory impairment of \$3,861,257 (2020 - \$Nil) due to the overall price compression within the cannabis industry, a decrease in fair value change on growth of biological asset of \$3,240,450 (2020 - \$4,767,202), and a fair value change in preferred shares of \$1,238,670 (2020 - \$1,896,095). The Company's general and administrative expense stayed relatively consistent at \$5,153,464 (2020 - \$5,151,368).
- For the year ended November 30, 2021, total revenue increased to \$3,633,450. This was the first year that revenue was recorded. The revenue was recorded from the sales of cannabis and cannabis derivatives to wholesale suppliers. All revenues earned is due to organic growth.
- Total assets increased to \$18,968,891 in 2021 from \$17,803,786 in 2020 and from \$6,202,790 in 2019. The Company has invested significantly to expand the Company's infrastructure and processing equipment. In addition, during the year ended November 30, 2020, the Company completed its first cannabis harvest, which increased inventory to \$6,222,808 (2019 - \$Nil). The Company's current assets increased to \$9,424,318 (2020 - \$8,268,936) mainly due to receivables increasing to \$1,072,519 (2020 - \$71,808) and the completion of the Company's second harvest.
- Total non-current financial liabilities increased in 2021 compared to 2020 mainly due to the reclassification of convertible debentures to current liabilities. Subsequent to the year ended November 30, 2021, the Company amended the terms of the preferred share and convertible debentures.

RESULTS OF OPERATIONS

For the year ended November 30, 2021 compared to the year ended November 30, 2020.

Revenue

The Company reported revenue from sale of goods of \$3,633,450 (2020 - \$Nil). The gross margin percentage for the year was 61% before fair value adjustment. During the three-month period ended November 30, 2021, the Company's revenue increased to \$2,063,569 (2021 Q3 - \$1,569,881). Sales in the quarter were primarily derived from distillate as production and demand continued to increase. During the three-month period ended November 30, 2021, sales volume for the Company's products increased by 31%, quarter over quarter. The gross margin percentage for the three-month period was 61% before fair value adjustment. In the comparative period, the Company was not in an income generating position.

Other results of operations

The Company recorded a loss and comprehensive loss of \$7,142,945 for the year ended November 30, 2021 compared to a net loss of \$2,852,639 for the corresponding period in 2020 as activities and revenue increased. During the year ended November 30, 2020, the Company was focused on the completion of the Company's facility and obtaining the necessary licensing. The Company obtained its standard processing license in September 2020 and finished commissioning equipment by February 2021. The 2021 calendar year is the first period where cultivation and processing activities were running simultaneously. The Company increased the size of the workforce which resulted in an increase in labor expenses. There were increases in depreciation expense due to building improvements and equipment purchases. There was a large inventory write down of \$3,861,257 and change in estimate of preferred shares of \$1,238,670 which contributed to the loss recorded.

Some of the significant charges to operations are as follows:

- Consulting fees of \$285,752 (2020 - \$417,771) decreased as the Company replaced some consulting services with full time employment to assist in the execution of the Company's business plan. In general, business operations increased substantially period over period and as such, the Company experienced an overall growth in consulting fees.
- Salaries of \$1,181,827 (2020 - \$911,620) increased from the previous financial period, as the Company hired several part-time and full-time employees as operations continued to ramp up.
- Marketing fees of \$469,707 (2020 - \$215,537) increased as the Company began building brand and market awareness.
- Professional fees of \$266,461 (2020 - \$336,372) increased as the Company ensured its compliance with reporting requirements in a highly regulated environment.
- Office and miscellaneous of \$291,661 (2020- \$277,779) increased as the Company ramped up business activity and started selling product throughout the fiscal year.
- Share based compensation of \$1,160,970 (2020 - \$2,370,971) decreased from the prior year due to a reduction in consultants used and turnover of officers.
- Interest expense on convertible debentures of \$472,531 (2020 - \$296,413) was incurred in the current period as convertible debentures were issued during the year ending November 30, 2020 to secure needed capital.
- Corporate development expense of \$548,810 (2020 - \$Nil) incurred in the current period used towards investor relation activities and non-recurring.

During the year ended November 30, 2021, the Company recorded a loss of \$7,142,945 compared to a loss of \$2,852,639 in the comparative period. Revenue grew by \$3,633,450 as compared to the prior comparative period as the company began sales in fiscal 2021. Income attributed to fair value change of biological assets was \$3,240,450 compared to \$4,767,202 in the comparative period of 2020. General and administrative expenses totalled \$5,153,464 up from \$5,151,368 as the Company ramped up operations for its second harvest, and first year's processing activities in conjunction with cultivation. Large non-cash item included in the general and administrative expenses include share – based compensation of \$1,160,970 (2020 - \$2,370,971). Large non-cash items included in the other items other than change in estimate of preferred shares mentioned above include accretion of \$368,625 (2020 - \$275,965), interest expense mainly related to convertible debentures of \$472,531 (2020 - \$296,413). There was a write down of inventory of \$3,861,257 (2020 - \$Nil) due to overall price compression within the cannabis industry.

SUMMARY OF QUARTERLY RESULTS

The table below presents selected financial data for the Company's eight most recently completed quarters, all prepared in accordance with IFRS.

	Nov 30, 2021 \$	Aug 31, 2021 \$	May 31, 2021 \$	Feb 28, 2021 \$
Revenue from sale of goods	2,063,569	1,290,722	216,738	62,421
Net income (loss)	(6,792,741)	3,779,843	(2,355,409)	(1,774,638)
Basic and diluted income (loss) per share	(0.06)	0.03	(0.02)	(0.02)
Balance sheet				
Total Assets	18,968,891	24,808,196	18,862,019	18,484,781
	Nov 30, 2020 \$	Aug 31, 2020 \$	May 31, 2020 \$	Feb 29, 2020 \$
Revenue from sale of goods	0.00	0.00	0.00	0.00
Net income (loss)	(2,337,460)	877,763	(788,364)	(604,578)
Basic and diluted income (loss) per share	(0.04)	0.01	(0.01)	(0.01)
Balance Sheet				
Total Assets	17,803,786	14,419,530	8,198,464	6,447,460

During the three months ending November 30, 2021, the Company reported revenue from sale of goods of \$2,063,569, compared to the revenue of \$1,290,722 reported the prior quarter. Sales in the quarter were primarily derived from the sale of distillate and kief as production continued to ramp up for both product lines. The gross margin percentage for the three-month period was 61% before fair value adjustment. For a more detailed analysis of expenses, please see fourth quarter results.

During the three months ending August 31, 2021 revenue from sales of goods totaled \$1,290,722 (2020 - \$Nil), which was an increase of \$1,073,984 from the prior quarter. Total direct costs before change in fair value were \$532,428, changes in fair value of inventory sold were \$742,593, and \$1,666,031 in general and administrative expenses of which share based compensation attributed a large portion of that expense of \$372,531 for shares issued to directors and officers. \$318,237 in Salaries are related to the growing and processing teams as operations ramped up. The Company recorded a biological asset fair value gain of \$5,430,173.

During the three months ending May 31, 2021 revenue from sales of goods totaled \$216,738 (2020 - \$Nil), which was an increase of \$154,317 from the prior quarter (first quarter that sales commenced). Total expenses were \$2,355,409, of which share-based compensation attributed a large portion of that expense of \$411,300 for shares issued to directors and officers. \$294,598 in salaries relate to the growing operations team ramping up, and \$292,859 in Marketing fees largely to continued brand development.

During the three months ending Feb 28, 2021 a first revenue from sales of goods of \$62,421 was recorded (2020 - \$Nil). The total General and Administrative expenses of \$1,770,936 grew as the Company was getting the Company's equipment and building ready for processing the 2020 crop. Larger General and Administrative expenses included salaries (\$425,163), depreciation (\$239,708), and corporate development (\$182,936).

During the three months ending November 30, 2020 net loss increased to \$2,337,460 (2019- \$506,922). The major components of the increase during the quarter related to an increase in estimate of the preferred share liability of (\$1,896,095), an increase in Share based compensation (\$941,194), salaries of (\$258,909), Office and Miscellaneous of (\$121,287), Professional fees of (\$114,106). This Loss was offset by an increase in the Fair Value change in Biological Assets of \$1,720,965.

SUMMARY OF QUARTERLY RESULTS (CONTINUED)

During the three months ending August 31, 2022 the Company reported an income of \$877,763 compared to the prior quarter where a loss of \$788,364 was reported, as it recorded a positive fair value adjustment on growth of biological asset of \$3,046,237 (prior quarter \$Nil), that turned the general and administrative loss of \$2,168,474 into an income.

During the three months ending May 31, 2020 the Company recorded a loss of \$788,364 as it was still building out the business. Total assets increased from \$6,447,460 the prior quarter to \$8,198,464 mainly due to proceeds received from convertible debentures issued during the quarter.

LIQUIDITY AND CAPITAL RESOURCES

The financial statements have been prepared on a going-concern basis, which assumes the realization of assets and liquidation of liabilities in the normal course of business. Continuing operations, as intended, are dependent on management's ability to raise required funding through future equity issuances, its ability to acquire resource property or business interests and develop profitable operations or a combination thereof, which is not assured, given today's volatile and uncertain financial markets. The Company may revise programs depending on its working capital position.

As at November 30, 2021 the Company had working capital of \$2,033,054 (2020 - \$6,453,751) which consisted of cash of \$1,075,666 (2020 - \$1,844,356), receivables of \$1,072,519 (2020 - \$71,808), prepaid expenses of \$122,755 (2020 - \$129,964), inventory including biological asset of \$7,153,378 (2020 - \$6,222,808). Current liabilities, being accounts payable and accrued liabilities, lease liabilities and current portion of preferred shares, and current portion of convertible debentures of \$7,391,264 (2020 - \$1,815,185).

Cash flows used in operating activities were \$4,620,580 compared to \$3,316,852 in the same period of 2020.

Cash used in investing activities for the year ended November 30, 2021 decreased to \$1,204,687 from \$4,782,984 for the same period in 2020. The large decrease is attributable to building improvements being mainly completed and less investment were required for equipment purchases.

Cash provided from financing activities for the year ended November 30, 2021 was \$5,056,577 compared to \$9,203,219 for the same period during the prior year. Net proceeds from private placements were \$3,615,182, from warrant exercises of \$1,170,200, and option exercises of \$306,305. Lease payments were \$31,200 (2020 - \$26,000).

Non-current liabilities for the year ended November 30, 2021, declined to \$1,838,438 from \$6,533,348 for the same period during the prior year. Convertible debentures bearing interest of 12% formed the bulk of this liability. The Company also has a Canada Emergency Business Account, "CEBA" \$40,000 of which 75% is payable December 31, 2023. The Company also have a long-term loan payable of \$6,517 (2020 - 10,427) for equipment. The Company has total current liabilities of \$7,391,264 (2020 - \$1,815,185).

Other than the above-mentioned current liabilities, the Company has no short-term capital spending requirements and future plans and expectations are based on the assumption that the Company will realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation.

There can be no assurance that the Company will be able to obtain adequate financing in the future or if available that such financing will be on acceptable terms. If adequate financing is not available when required, the Company may be required to delay, scale back or eliminate various programs and may be unable to continue in operation. The Company may seek such additional financing through debt or equity offerings. Any equity offering will result in dilution to the ownership interests of the Company's shareholders and may result in dilution to the value of such interests.

OFF-BALANCE SHEET ARRANGEMENTS

The Company has not entered into any off-balance sheet arrangements.

TRANSACTIONS WITH RELATED PARTIES

The Executive Officers and Directors of the Company are as follows:

Mervin Boychuk	Director, non-executive chairman of BOD
Gil Playford	Director
Salvatore Milia	Director
Jay McMillan	Director
Joel Dumaresq	CEO and Director
Nicco Dehaan	COO and Director
Ryan Smith	CFO
Ray Baterina	Corporate Secretary
Robert Jones	President

The Company has identified its directors and certain senior officers as its key management personnel. During the year, the Company entered into transactions with related parties comprised of directors, officers and companies with common directors. The key management compensation and director fees consist of the following for the year ended November 30, 2021 and November 30, 2020:

	November 30, 2021 \$	November 30, 2020 \$
Accounting fees included in Professional fees paid to the CFO	87,524	-
Consulting fees paid to a previous director of the Company	-	10,000
Consulting fees paid to a private company jointly controlled by the CEO	-	238,289
Consulting fees paid to an officer of the Company	114,679	-
Lease payments to a company controlled by a director	31,200	-
Management fees paid to CEO	144,000	45,325
Salaries paid to key management	278,750	254,371
Share based payments	402,021	414,141
Shares issued in lieu of cash for consulting fees	23,750	375,000
	1,081,924	1,337,126

As at November 30, 2021, there was \$185,748 (November 30, 2020 - \$396,720) included in accounts payable and accrued liabilities for related parties of the Company. The balance is unsecured, due on demand and are non-interest bearing.

During the year ended November 30, 2021, the Company paid rent of \$6,500 to a private company jointly controlled by the CEO (2020 - \$6,500).

During the year ended November 30, 2021, the Company paid lease payments of \$31,200 to a private company controlled by a director (2020- \$20,800).

During the year ending November 30, 2021, the Company has an obligation to issue 500,000 shares (2020 - 250,000 shares) to the CEO in lieu of cash for consulting fees in the amount of \$23,750 (2020 - \$89,500).

During the year ended November 30, 2021, the Company issued convertible debentures to directors and officers of the Company in aggregate principal amount of \$Nil (2020 - \$230,000).

The Company was obligated to issue 604,110 shares to the former CEO of the Company as part of his employment agreement, which is recorded as obligation to issue shares of \$104,932 at November 30, 2019. Consequently, 604,110 shares were issued during the year ended November 30, 2020.

FOURTH QUARTER RESULTS

Revenue

During the fourth quarter of 2021, the Company reported revenue from sale of goods of \$2,063,569 compared to the previous year of \$Nil. This amounts to an increase of \$2,063,569 from the same quarter during the prior year when the Company reported \$Nil. The gross margin percentage for the three-month period was 61% before fair value adjustment. In the comparative period, during the prior year, the Company was not in a net income generating position.

Other results of operations

During the fourth quarter, the Company recorded a loss and comprehensive loss of \$6,792,741 for the period ended November 30, 2021 compared to a net loss of \$2,337,460 for the corresponding period in 2020 as activities and revenue increased. For much of 2020 the Company was still in the final construction and licensing phases. The Company obtained their processing license in September 2020 and finished commissioning equipment by February 2021. During the fourth quarter ending November 30, 2021, the Company recorded a revenue of \$2,063,569 (2020 - \$Nil) and a gross profit before fair value adjustment of inventory sold of \$1,257,530. The Company increased the size of the workforce which is resulted in an increase in labor expenses. Total expenses decreased with \$1,211,995. The net loss for the fourth quarter increased with \$4,455,281, as the current quarter reported a write down of 2020 inventory of \$3,861,257 (2020 - \$Nil) and a fair value change of preferred shares of \$728,149 (2020 - \$1,896,095).

Some of the significant charges to operations are as follows:

- Revenue of \$2,063,569 (2020 - \$Nil) was recorded as the business entered the first year of sales.
- Cost of sales of \$806,039 (\$2020 - \$Nil) was reported in quarter four.
- Changes in fair value of inventory sold of \$607,880 (2020 - \$Nil) as no sales took place in the same quarter the previous year.
- Fair value change of the biological asset of \$2,189,723 (2020 - \$1,720,965)
- Salaries of \$143,829 (2020 - \$258,909) decreased from the previous financial period.
- Marketing fees of \$65,823 (2020 - \$215,537) decreased as the Company spent less on marketing.
- Professional fees of \$(131,634) (2020 - \$114,106) decreased as the Company established systems in place to comply with reporting requirements in a highly regulated environment. Savings was mainly recorded in legal expenses. The credit balance to professional fees is due to certain expense reclassifications that occurred during the fourth quarter.
- Office and miscellaneous of \$61,077 (2020- \$116,787) remained relatively flat incurred various expenditures related to the day-to-day operations.
- Share based compensation of \$236,035 (2020 - \$941,194) decreased from the same quarter in the prior year due to a reduction in consultants used and turnover of officers.
- Interest expense on convertible debentures of \$(19,820) (2020 - \$119,511) was incurred, as convertible debentures was issued during the year ending November 30, 2020 to secure needed capital. As conversion and redemption of these convertible debentures takes place, the interest expense is expected to decreases. During the fourth quarter, the Company re-calculated interest expense on its convertible debenture for the year resulting in a credit balance for the three month period ended November 30, 2021.
- Corporate Development expense of \$182,938 (2020 - \$Nil) was incurred in the current period as to ensure smooth operations of the Company's developing business. Included in that total was a larger expense which is non-recurring beyond the next quarter.

PROPOSED TRANSACTIONS

As at the date of this MD&A, there are no proposed transactions.

CRITICAL ACCOUNTING ESTIMATES AND SIGNIFICANT JUDGEMENTS

Significant estimates and assumptions

The preparation of the Company's financial statements in conformity with IFRS requires management to make estimates and assumptions concerning the future. Estimates and assumptions are continuously evaluated and are based on management's experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. However, actual outcomes can differ from these estimates.

Areas requiring a significant degree of estimation relate to the fair value measurements for financial instruments and biological assets, discount rate on lease liability, convertible debentures and preferred shares, assumptions used in the cash flow projection for preferred shares, useful lives and valuation of property, plant and equipment, valuation of inventory and the recoverability and measurement of deferred tax assets and liabilities. Actual results may differ from those estimates.

Management is required to make a number of estimates in calculating the fair value less costs to sell of biological assets. These estimates include a number of assumptions such as estimating the stage of growth of the cannabis, harvesting costs, sales price, and expected yields.

Significant judgments

The preparation of financial statements in accordance with IFRS requires the Company to make judgments, apart from those involving estimates, in applying accounting policies. The most significant judgments in applying the Company's financial statements include: the classification of expenditures as building improvements to be capitalized or as operating costs which are expensed; the assessment of the Company's ability to continue as a going concern and whether there are events or conditions that may give rise to a significant uncertainty.

FINANCIAL INSTRUMENTS AND RISKS

The Company is exposed in varying degrees to a variety of financial instrument related risks. The Board of Directors approves and monitors the risk management processes, inclusive of documented investment policies, counterparty limits, and controlling and reporting structures. The type of risk exposure and the way in which such exposure is managed is provided as follows:

Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's primary exposure to credit risk is on its cash held in bank accounts and accounts receivable. The majority of cash is deposited in bank accounts held with a major bank in Canada. As most of the Company's cash is held by one bank there is a concentration of credit risk. This risk is managed by using major banks that are high credit quality financial institutions as determined by rating agencies. Credit risk related to cash is assessed as low.

The Company provides credit to certain customers in the normal course of operations. Credit risk is generally limited to receivables from arm's length customers. The Company's credit risk related to its receivables is moderate. At November 30, 2021, the Company had no material receivable balances past due and the balances were collected subsequent to November 30, 2021. The Company has established monitoring processes to mitigate credit risk.

FINANCIAL INSTRUMENTS AND RISKS (CONTINUED)

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company has a planning and budgeting process in place to help determine the funds required to support the Company's normal operating requirements on an ongoing basis. The Company ensures that there are sufficient funds to meet its short-term business requirements, taking into account its anticipated cash flows from operations and its holdings of cash. As of November 30, 2021, the Company has cash of \$1,075,666 (2020 - \$1,844,356) to cover short term obligations.

Historically, the Company's sole source of funding has been loans from related parties, convertible debentures, preferred share financings and private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding. Liquidity risk is assessed as high.

The Company has the following contractual obligations as at November 30, 2021, which are expected to be payable in the following respective periods:

	Total	≤ 1 year	Over 1 year – 3 years
Accounts payable	559,607	559,607	-
Loan payable	10,427	3,910	6,517
Lease liability	4,651	4,651	-
Preferred shares	4,858,767	3,057,414	1,801,353
Government loan	30,568	-	30,568
Convertible debentures	3,765,682	3,765,682	-
Total	9,229,702	7,391,264	1,838,438

Foreign exchange risk

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. The Company is not exposed to foreign exchange risk.

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. As at November 30, 2021, the Company has convertible debentures of \$3,765,682 and government loans of \$30,568, which bears a fixed interest rate and a nil interest rate, respectively. As such, the Company's interest rate risk is low.

Capital Management

The Company's policy is to maintain a strong capital base so as to maintain investor and creditor confidence and to sustain future development of the business. The capital structure of the Company consists of equity and cash. There were no changes in the Company's approach to capital management during the year. The Company is not subject to any externally imposed capital requirements.

ADDITIONAL SHARE INFORMATION

As at the date of this MD&A, the Company had 129,642,173 common shares issued and outstanding. The Company has 14,549,477 warrants outstanding, 950,000 restricted stock units, and 10,923,400 stock options outstanding.

CONTINGENCIES

The Company is not aware of any contingencies or pending legal proceedings as of the date of this report.

CAUTIONARY STATEMENT ON FORWARD LOOKING INFORMATION

Certain statements contained in this document constitute "forward-looking statements". Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressly stated or implied by such forward-looking statements.

DISCLAIMER

The information provided in this document is not intended to be a comprehensive review of all matters concerning the Company. The users of this information, including but not limited to investors and prospective investors, should read it in conjunction with all other disclosure documents provided including but not limited to all documents filed on SEDAR. No securities commission or regulatory authority has reviewed the accuracy or adequacy of the information presented herein.

RISK FACTORS

The following are certain risk factors relating to the business carried on by the Company that prospective holders of Shares should carefully consider.

Warrants are Speculative in Nature and may not have any Value

The Warrants do not confer any rights of Common Share ownership on their holders, such as voting rights or the right to receive dividends, but rather merely represent the right to acquire Common Shares at a fixed price for a limited period of time. Moreover, the market value of the Warrants, if any, is uncertain and there can be no assurance that the market value of the Warrants will equal or exceed their imputed offering price. There can be no assurance that the market price of the Common Shares will ever equal or exceed the exercise price of the Warrants, and consequently, whether it will ever be profitable for holders of the Warrants to exercise their Warrants.

Volatility of Stock Price and Market Conditions

The market price of the Common Shares may be subject to wide fluctuations in response to factors such as actual or anticipated variations in its results of operations, changes in financial estimates by securities analysts, general market conditions and other factors. Market fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may adversely affect the market price of the Common Shares, even if the Company is successful in maintaining revenues, cash flows or earnings. The purchase of the Common Shares involves a high degree of risk and should be undertaken only by investors whose financial resources are sufficient to enable them to assume such risks and who have no need for immediate liquidity in their investment. Securities of the Company should not be purchased by persons who cannot afford the possibility of the loss of their entire investment. Furthermore, an investment in the Company should not constitute a major portion of an investor's portfolio.

Risk Factors Associated with the Company's Business

The following are certain risk factors relating to the business carried on by the Company that prospective holders of Shares should carefully consider.

Negative Cash Flow from Operations

During the year ended November 30, 2021, the Company sustained net losses from operations. The Company's cash as at November 30, 2021 was approximately \$1,075,666. Although the Company anticipates it will have positive cash flow from operating activities in future periods, it is possible the Company may have negative cash flow in any future period as the Company continues to progress its expansion plans and its capacity of operations.

Reliance on Licenses

The Company will be dependent on the Licenses, which is subject to ongoing compliance and reporting requirements. Failure to comply with the requirements of these licenses or any failure to obtain or maintain those licenses could have a material adverse impact on the business, financial condition and operating results of the Corporation. There can be no guarantee that a license will be issued, extended or renewed or, if issued, extended or renewed, that it will be issued, extended or renewed on terms that are favorable to the Company.

In Canada, few applicants for a license from Health Canada ultimately receive a license to produce and sell cannabis. Major expenditures may be required in pursuit of a license and it is impossible to ensure that the expenditures will result in receipt of a license and a profitable operation. There can be no assurances that the Company will maintain a license to produce and sell cannabis and be brought into a state of commercial production. Should a license not be extended or renewed or should it be issued or renewed on terms that are less favorable to the Company than anticipated, the business, financial condition and results of the operations of the Company could be materially adversely affected.

Environmental Regulations and Risks

The Company's operations are subject to environmental regulation in the various jurisdictions in which it operates. These regulations mandate, among other things, the maintenance of air and water quality standards and land reclamation. They also set forth limitations on the generation, transportation, storage and disposal of solid and hazardous waste. Environmental legislation is evolving in a manner which will require stricter standards and enforcement, increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a heightened degree of responsibility for companies and their officers, directors and employees. There is no assurance that future changes in environmental regulation, if any, will not adversely affect the Company's operations.

Government approvals and permits are currently and may in the future be required in connection with the Company's operations. To the extent such approvals are required and not obtained, the Company may be curtailed or prohibited from its proposed production of cannabis or from proceeding with the development of its operations as currently proposed.

Failure to comply with applicable laws, regulations and permitting requirements may result in enforcement actions thereunder, including orders issued by regulatory or judicial authorities causing operations to cease or be curtailed, and may include corrective measures requiring capital expenditures, installation of additional equipment, or remedial actions. The Company may be required to compensate those suffering loss or damage by reason of its operations and may have civil or criminal fines or penalties imposed for violations of applicable laws or regulations.

Amendments to current laws, regulations and permits governing the production of cannabis, or more stringent implementation thereof, could have a material adverse impact on the company and cause increases in expenses, capital expenditures or production costs or reduction in levels of production or require abandonment or delays in development.

RISK FACTORS (CONTINUED)

Early Stage of Development

The Company, while incorporated in 2014, began carrying on business in 2018 and has started to generate profits from the sale of products late in 2021. The Company is therefore subject to many of the risks common to early-stage enterprises, including under-capitalization, cash shortages, limitations with respect to personnel, financial, and other resources and lack of revenues. There is no assurance that the Company will be successful in achieving a return on shareholders' investment and the likelihood of success must be considered in light of the early stage of operations.

Cultivation Risks

The Company's business involves the growing of cannabis, an agricultural product. Such business will be subject to the risks inherent in the agricultural business, such as insects, plant diseases and similar agricultural risks. Although the Company expects that any such growing will be completed indoors under climate-controlled conditions, and outdoors, there can be no assurance that natural elements will not have a material adverse effect on any such future production.

Legislative or Regulatory Reform and Compliance

The commercial cannabis industry is a new industry and the Company anticipates that such regulations will be subject to change as the Federal Government monitors Licensed Producers in action. The Company's operations are subject to a variety of laws, regulations, guidelines and policies relating to the manufacture, import, export, management, packaging/labelling, advertising, sale, transportation, storage and disposal of cannabis but also including laws and regulations relating to drugs, controlled substances, health and safety, the conduct of operations and the protection of the environment. While to the knowledge of management, the Company is currently in compliance with all such laws, any changes to such laws, regulations, guidelines and policies due to matters beyond the control of the Company may cause adverse effects to its operations.

Changes in Laws, Regulations and Guidelines

On December 20, 2017, the Prime Minister communicated that the Canadian Federal Government intends to legalize cannabis in the summer of 2018, despite previous reports of a July 1, 2018 deadline. On June 7, 2018, Bill C45 passed the third reading in the Senate with a number of amendments to the language of the Cannabis Act. On June 20, 2018, Prime Minister Trudeau announced that cannabis would be legal by October 17, 2018. On June 21, 2018, the Government of Canada announced that Bill C-45 received Royal Assent. Bill-C-45 will come into force on October 17, 2018. On July 11, 2018, the regulations made pursuant 27 to the Cannabis Act were published. The regulations under the Cannabis Act contemplate the various licenses including cultivation, processing, analytical testing, sale (including medical sales), analytical testing and scientific research. The regulations introduced the nursery and made outdoor cultivation permissible. Finally, the requirements for packaging and labelling of products for both medical and non-medical consumption were explicitly set forth. The impact of changes in the regulatory enforcement by Health Canada under the Cannabis Act and its regulations, particularly in respect of product packaging, labelling, marketing, advertising and promotions and product approvals and its impact on the Company's business are unknown at this time.

In addition, when the Cannabis Act comes into effect, there is no guarantee that provincial legislation regulating the distribution and sale of cannabis for adult use purposes will be enacted according to the terms announced by such provinces, or at all, or that any such legislation, if enacted, will create the opportunities for growth anticipated by the Company. For example, the Provinces of Québec and New Brunswick have announced sales and distribution models that would create government-controlled monopolies over the legal retail and distribution of cannabis.

RISK FACTORS (CONTINUED)

Negative Customer Perception

The Company believes the cannabis industry is highly dependent upon consumer perception regarding the medical benefits, safety, efficacy and quality of the cannabis distributed for medical purposes to such consumers. Consumer perception of the Company's products can be significantly influenced by scientific research or findings, regulatory investigations, litigation, political statements both in Canada and in other countries, media attention and other publicity (whether or not accurate or with merit) regarding the consumption of cannabis products for medical or recreational purposes, including unexpected safety or efficacy concerns arising with respect to the products of the Company or its competitors. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the medical cannabis market or any particular product, or consistent with earlier publicity. Future research reports, findings, regulatory proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for the Company's products and the business, results of operations and financial condition of the Company. The Company's dependence upon consumer perceptions means that adverse scientific research reports, findings, regulatory proceedings, litigation, media attention or other publicity (whether or not accurate or with merit), could have an adverse effect on any demand for the Company's products which could have a material adverse effect on the Company's business, financial condition and results of operations.

Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of cannabis for medical purposes in general, or the Company's products specifically, or associating the consumption of cannabis with illness or other negative effects or events, could have such a material adverse effect. Such adverse publicity reports or other media attention could arise even if the adverse effects associated with such products resulted from consumers' failure to consume such products legally, appropriately or as directed.

Constraints on Marketing Products

In view of the restrictions on marketing, advertising and promotional activities set forth in the Cannabis Act and related regulations, the Company's business and operating results may be hindered by applicable restrictions on sales and marketing activities imposed by Health Canada. If the Company is unable to effectively market its products and compete for market share, or if the costs of compliance with government legislation and regulation cannot be absorbed through increased selling prices for its products, the Company's sales and operating results could be adversely affected.

Reliance on Receiving a Research and Development License and subsequent Cultivation and Processors License

The Company's ability to set up its Facility for the purposes of research and development and to grow, store and sell cannabis in Canada is dependent on Health Canada's approval of the Company's RDL and subsequent cultivation and processor licenses (the "Licenses"). The Licenses are subject to ongoing compliance and reporting requirements. Failure to comply with the requirements of the Licenses or any failure to maintain the Licenses would have a material adverse impact on the business, financial condition and operating results of the Company. Although the Company believe they will meet the requirements for future extensions or renewals of the Licenses, there can be no guarantee that Health Canada will extend or renew these Licenses or, if extended or renewed, that they will be extended or renewed on the same or similar terms. Should Health Canada not extend or renew the Licenses or should they renew the Licenses on different terms, the business, financial condition and results of the operation of the Company would be materially adversely affected

RISK FACTORS (CONTINUED)

New product Development

The Company's ability to sell cannabis in Canada is dependent on the Company's ability to develop product that exceeds the standards set by Health Canada. Although the Company believes management has the expertise to develop such products, there is no assurance that the Company will successfully develop new products.

Competition

There is potential that the Company will face intense competition from other companies, some of which can be expected to have longer operating histories and more financial resources and experience than the Company. Currently, the cannabis industry generally is comprised of individuals and small to medium-sized entities, however, the risk remains that large conglomerates and companies who also recognize the potential for financial success through investment in this industry could strategically purchase or assume control of certain aspects of the industry. In doing so, these larger competitors could establish price setting and cost controls which would effectively "price out" many of the individuals and small to medium-sized entities who currently make up the bulk of the participants in the varied businesses operating within and in support of the medical and adult-use cannabis industry. While most laws and regulations seemingly deter this type of takeover, this industry remains quite nascent, so what the landscape will be in the future remains largely unknown, which in itself is a risk. Because of the early stage of the industry in which the Company will operate, the Company expects to face additional competition from new entrants. To become and remain competitive, the Company will require research and development, marketing, sales and support.

Liability, Enforcement Complaints, etc.

The Company's participation in the cannabis industry may lead to litigation, formal or informal complaints, enforcement actions, and inquiries by various federal, provincial, or local governmental authorities against it. Litigation, complaints, and enforcement actions involving the business could consume considerable amounts of financial and other corporate resources, which could have an adverse effect on the Company's future cash flows, earnings, results of operations and financial condition.

Additional Financing

The Company may require equity and/or debt financing to undertake capital expenditures or to undertake acquisitions or other business combination transactions. There can be no assurance that additional financing will be available to the Company when needed or on terms that are commercially viable. The Company's inability to raise financing to fund capital expenditures or acquisitions could limit its growth and may have a material adverse effect upon future profitability.

If additional funds are raised through further issuances of equity or convertible debt securities, existing shareholders could suffer significant dilution. Any debt financing secured in the future could involve restrictive covenants relating to capital raising activities and other financial and operational matters, which may make it more difficult for the Company to obtain additional capital and to pursue business opportunities, including potential acquisitions.

Reliance on Management

The success of the Company is dependent upon the ability, expertise, judgment, discretion and good faith of its senior management and employees. While employment agreements or management agreements are customarily used as a primary method of retaining the services of key employees, these agreements cannot assure the continued services of such employees. Any loss of the services of such individuals could have a material adverse effect on the Company's business, operating results or financial condition.

RISK FACTORS (CONTINUED)

Operation Permits and Authorizations

The Company may not be able to obtain or maintain the necessary licenses, permits, authorizations or accreditations, or may only be able to do so at great cost, to operate the businesses. In addition, the Company may not be able to comply fully with the wide variety of laws and regulations applicable to the cannabis industry. Failure to comply with or to obtain the necessary licenses, permits, authorizations or accreditations could result in restrictions on a Licensee's ability to operate in the cannabis industry, which could have a material adverse effect on the Company's business.

Product Liability

Certain of the Company's proposed manufacture, process and/or distribute of cannabis products are designed to be ingested by humans, and therefore face an inherent risk of exposure to product liability claims, regulatory action and litigation if products are alleged to have caused significant loss or injury. In addition, previously unknown adverse reactions resulting from human consumption of cannabis alone or in combination with other medications or substances could occur. A product liability claim or regulatory action against the Company could result in increased costs, could adversely affect the Company's reputation, and could have a material adverse effect on the results of operations and financial condition of the Company.

Reliance on Key Inputs

The cultivation, extraction and processing of cannabis and derivative products is dependent on a number of key inputs and their related costs including raw materials, electricity, water and other local utilities. Any significant interruption or negative change in the availability or economics of the supply chain for key inputs could materially impact the business, financial condition and operating results of the Company. Some of these inputs may only be available from a single supplier or a limited group of suppliers.

If a sole source supplier was to go out of business, the Company might be unable to find a replacement for such source in a timely manner or at all. Any inability to secure required supplies and services or to do so on appropriate terms could have a materially adverse impact on the business, financial condition and operating results of the Company.

Dividends

The Company does not anticipate paying any dividends in the foreseeable future. Dividends paid by the Company would be subject to tax and, potentially, withholdings.

Resale of Shares

There can be no assurance that there will be an active and liquid market for the Shares will develop or be maintained and an investor may find it difficult to resell any securities of the Company. In addition, there can be no assurance that the publicly-traded stock price of the Company will be high enough to create a positive return for investors. Further, there can be no assurance that the stock of the Company will be sufficiently liquid so as to permit investors to sell their position in the Company without adversely affecting the stock price. In such event, the probability of resale of the Company's shares would be diminished.

Price Volatility of Publicly Traded Securities

In recent years, the securities markets in the United States and Canada have experienced a high level of price and volume volatility, and the market prices of securities of many companies have experienced wide fluctuations in price which have not necessarily been related to the operating performance, underlying asset values or prospects of such companies. There can be no assurance that continuing fluctuations in price will not occur. It may be anticipated that any quoted market for the shares of the Company will be subject to market trends generally, notwithstanding any potential success of the Company in creating revenues, cash flows or earnings. The value of the Company's shares will be affected by such volatility. An active public market for the Company's shares might

RISK FACTORS (CONTINUED)

Price Volatility of Publicly Traded Securities (continued)

not develop or be sustained after the completion of the listing. If an active public market for the Company's shares does not develop, the liquidity of a shareholder's investment may be limited and the share price may decline.

Management of Growth

The Company may experience a period of significant growth in the number of personnel that will place a strain upon its management systems and resources. Its future will depend in part on the ability of its officers and other key employees to implement and improve financial and management controls, reporting systems and procedures on a timely basis and to expand, train, motivate and manage the workforce. The Company's current and planned personnel, systems, procedures and controls may be inadequate to support its future operations.

Intellectual Property

The success of the Company will depend, in part, on the ability to maintain and enhance trade secret protection over the various existing and potential proprietary techniques and processes of the Company. The Company may be vulnerable to competitors who develop competing technology, whether independently or as a result of acquiring access to the proprietary products and trade secrets of the Company. In addition, effective future patent, copyright and trade secret protection may be unavailable or limited in certain foreign countries and may be unenforceable under the laws of certain jurisdictions.

Insurance Coverage

The Company will require insurance coverage for a number of risks. Although Management believes that the events and amounts of liability covered by such insurance policies should be reasonable, taking into account the risks relevant to the Company's business, and the fact that agreements with users contain limitations of liability, there can be no assurance that such coverage will be available or sufficient to cover claims to which the Company may become subject. If insurance coverage is unavailable or insufficient to cover any such claims, the Company's financial resources, results of operations and prospects, could be adversely affected.

Costs of Maintaining a Public Listing

As a public company, there are costs associated with legal, accounting and other expenses related to regulatory compliance. Securities legislation and the rules and policies of the CSE require listed companies to, among other things, adopt corporate governance and related practices, and to continuously prepare and disclose material information, all of which add to a company's legal and financial compliance costs. The Company may also elect to devote greater resources than it otherwise would have on communication and other activities typically considered important by publicly traded companies.

RISK FACTORS (CONTINUED)

Litigation

The Company may become party to litigation from time to time in the ordinary course of business which could adversely affect its business. Should any litigation in which the Company becomes involved be determined against the Company, such a decision could adversely affect the Company's ability to continue operating and the market price for Shares and could use significant resources. Even if the Company is involved in litigation and wins, litigation can redirect significant resources.

Difficulty Implementing Business Strategy

The growth and expansion of the Company is heavily dependent upon the successful implementation of its business strategy. There can be no assurance that the Company will be successful in the implementation of its business strategy.

Operational Risks

The Company may be affected by a number of operational risks and may not be adequately insured for certain risks, including: labor disputes; catastrophic accidents; fires; blockades or other acts of social activism; changes in the regulatory environment; impact of non-compliance with laws and regulations; natural phenomena, such as inclement weather conditions, floods, earthquakes and ground movements. There is no assurance that the foregoing risks and hazards will not result in damage to, or destruction of, the Company's Property and Facility, personal injury or death, environmental damage, adverse impacts on the Company's operations, costs, monetary losses, potential legal liability and adverse governmental action, any of which could have an adverse impact on the Company's future cash flows, earnings and financial condition on the Company. Also, the Company may be subject to or affected by liability or sustain loss for certain risks and hazards against which they may elect not to insure because of the cost. This lack of insurance coverage could have an adverse impact on the Company's future cash flows, earnings, results of operations and financial condition.

Conflicts of Interest

Certain of the Company's directors and officers are, and may continue to be, involved in other business ventures through their direct and indirect participation in corporations, partnerships, joint ventures, etc. that may become potential competitors of the technologies, products and services the Company intends to provide. Situations may arise in connection with potential acquisitions or opportunities where the other interests of these directors' and officers' conflict with or diverge from the Company's interests. In accordance with applicable corporate law, directors who have a material interest in or who is a party to a material contract or a proposed material contract with the Company are required, subject to certain exceptions, to disclose that interest and generally abstain from voting on any resolution to approve the contract. In addition, the directors and officers are required to act honestly and in good faith with a view to the Company's best interests.

However, in conflict-of-interest situations, the Company's directors and officers may owe the same duty to another company and will need to balance their competing interests with their duties to the Company. Circumstances (including with respect to future corporate opportunities) may arise that may be resolved in a manner that is unfavorable to the Company.

Available Talent Pool

As the Company grows, it will need to hire additional human resources to continue to develop the business. However, experienced talent in the areas of cannabis research and development, cultivation of cannabis and extraction is difficult to source, and there can be no assurance that the appropriate individuals will be available or affordable to the Company. Without adequate personnel and expertise, the growth of the Company's business may suffer.

RISK FACTORS (CONTINUED)

Ability to Maintain Bank Accounts

While the Company does not anticipate any banking restrictions at this time, there is a risk that banking institutions may not accept payments related to the cannabis industry. Such risks could increase costs for the Company. In the event financial service providers do not accept accounts or transactions related to the cannabis industry, it is possible that the Company may be required to seek alternative payment solutions. If the industry was to move towards alternative payment solutions the Company would have to adopt policies and protocols to manage these changes. The Company's inability to manage such risks may adversely affect the Company's operations and financial performance.

Cautionary Statement

Statements contained in this MD&A that are not historical facts are forward-looking statements (within the meaning of the Canadian securities legislation that involve risks and uncertainties. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible" or variations of such words and phrases or the negative connotation thereof, or statements that events, conditions or results "will", "may", "could" or "should" occur or be achieved. The forward-looking statements may include statements regarding future financial conditions, results of operations, plans, objectives, performance or business developments, capital expenditures, timelines, strategic plans, market or industry growth, evaluation of the potential impact of future accounting changes, share-based payments and carrying value of intangible assets or other statements that are not statements of fact. Forward-looking statements are statements about the future and are inherently uncertain, and actual achievements of the Company may differ materially from those reflected in forward-looking statements due to a variety of risks, uncertainties and other factors.

Risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements include, without limitation,

- treatment under government regulatory and taxation regimes;
- expectations regarding the Company's ability to raise capital;
- the Company's business strategies, intentions to develop its business and operations, objectives and plans to pursue the commercialization of its products;
- expectations for expansion plans for the Facility and its costs;
- the suitability of the Facility;
- expectations regarding production costs, capacity and yields of the Company's business and growth thereof;
- the Company's estimates of the size of the potential markets for its products and the rate and degree of market acceptance of such products and its competitive positions in relation thereto;
- projections of market prices and costs and the future market for the Company's products and conditions affecting same;
- estimates of the Company's future revenues and profits;
- the Company's anticipated cash needs, needs for additional financing and use of funds;
- statements relating to the business and future activities of, and developments related to the Company after the date of this Listing Statement and thereafter; and
- liquidity of the Common Shares following listing of the Shares.

RISK FACTORS (CONTINUED)

Cautionary Statement (Continued)

The actual results could differ materially from those anticipated in these forward-looking statements as a result of the risk factors set forth below and elsewhere in this MD&A:

- treatment under government regulatory and taxation regimes and potential changes thereto;
- limited operating history and negative operating cash flow;
- reliance by the Company on a single production facility and factors relating to the development of the Facility;
- expansion plans for the Facility being subject to Health Canada regulatory approvals;
- dependence on management and conflicts of interest;
- restrictions on marketing activities in the medical cannabis industry;
- competition for, among other things, customers, land and greenhouses, supply, capital, capital acquisitions of products and skilled personnel;
- consumer acquisition and retention;
- risks and liabilities inherent in medical cannabis and agricultural operations;
- unfavorable publicity or consumer perception;
- product liability and recall risks as well as general operating risks;
- environmental risks;
- availability of financing opportunities;
- risks relating to global financial and economic conditions;
- future liquidity and financial capacity; and
- other factors discussed under “*Risk Factors*”.

It is the Company's policies that all forward-looking statements are based on the Company's beliefs and assumptions which are based on information available at the time these assumptions are made. The forward-looking statements contained herein are based on information available as at the date of this report and are subject to change after this date. Forward-looking statements are subject to a number of known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from that which was expressed or implied by such forward looking statements. Consequently, all forward-looking statements made in this MD&A are qualified by such cautionary statements and there can be no assurance that the anticipated results or developments will actually be realized or, even if realized, that they will have the expected consequences to or effects on the Company. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. These forward-looking statements are made as of the date of this MD&A and, other than as required by applicable securities laws, the Company assumes no obligation to update or revise them to reflect new events or circumstances.